keyword
MENU ▼
Read by QxMD icon Read
search

R-chop

keyword
https://www.readbyqxmd.com/read/28525305/clinical-impact-of-the-cell-of-origin-classification-and-the-myc-bcl2-dual-expresser-status-in-diffuse-large-b-cell-lymphoma-treated-within-prospective-clinical-trials-of-the-german-high-grade-non-hodgkin-s-lymphoma-study-group
#1
Annette M Staiger, Marita Ziepert, Heike Horn, David W Scott, Thomas F E Barth, Heinz-Wolfram Bernd, Alfred C Feller, Wolfram Klapper, Monika Szczepanowski, Michael Hummel, Harald Stein, Dido Lenze, Martin-Leo Hansmann, Sylvia Hartmann, Peter Möller, Sergio Cogliatti, Georg Lenz, Lorenz Trümper, Markus Löffler, Norbert Schmitz, Michael Pfreundschuh, Andreas Rosenwald, German Ott
Purpose To explore the prognostic impact and interdependence of the cell-of-origin (COO) classification, dual expression (DE) of MYC and BCL2 proteins, and MYC, BCL2, and BCL6 translocations in two prospectively randomized clinical trials of patients with diffuse large B-cell lymphoma (DLBCL). Patients and Methods Overall, 452 formalin-fixed paraffin-embedded samples from two prospective, randomized DLBCL trials (RICOVER-60, prospective, randomized study for patients > 60 years, all IPI groups; and R-MegaCHOEP, prospective, randomized study for patients ≤ 60 years with age-adjusted IPI 2,3) of the German High-Grade Non-Hodgkin Lymphoma Study Group were analyzed with the Lymph2Cx assay for COO classification, with immunohistochemistry for MYC and BCL2, and with fluorescent in situ hybridization for MYC, BCL2, and BCL6 rearrangements...
May 19, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28524259/nonpegylated-liposomal-doxorubicin-combination-regimen-in-patients-with-diffuse-large-b-cell-lymphoma-and-cardiac-comorbidity-results-of-the-heart01-phase-ii-trial-conducted-by-the-fondazione-italiana-linfomi
#2
Stefano Luminari, Elda Viel, Andrés José Maria Ferreri, Francesco Zaja, Emanuela Chimienti, Gerardo Musuraca, Alessandra Tucci, Monica Balzarotti, Monica Tani, Francesca Salvi, Emanuela A Pesce, Angela Ferrari, Anna M Liberati, Antonio Spadea, Dario Marino, Maria Bruno-Ventre, Stefano Volpetti, Chiara Bottelli, Elena Ravaioli, Francesco Merli, Michele Spina
The purpose of this phase 2, multicenter study was to determine the activity and safety of nonpegylated liposomal doxorubicin as part of "R-COMP" combination in patients with diffuse large B-cell lymphoma and coexisting cardiac disorders. The study was conducted using a Bayesian continuing assessment method using complete remission rate and rate of cardiac events as study endpoints. Between November 2009 and October 2011, 50 evaluable patients were enrolled (median age, 76 years). Median baseline left ventricular ejection fraction (LVEF) was 60%...
May 19, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28522442/bcl2-expression-in-dlbcl-reappraisal-of-immunohistochemistry-with-new-criteria-for-therapeutic-biomarker-evaluation
#3
Naoko Tsuyama, Seiji Sakata, Satoko Baba, Yuko Mishima, Noriko Nishimura, Kyoko Ueda, Masahiro Yokoyama, Yasuhito Terui, Kiyohiko Hatake, Masanobu Kitagawa, Naoki Ishizuka, Naoto Tomita, Kengo Takeuchi
Overexpression of the BCL2 is associated with a poor prognosis in diffuse large B-cell lymphoma (DLBCL). The assessment of MYC immunohistochemistry (IHC) is becoming optimized, whereas the criteria for BCL2 positivity are highly variable. Furthermore, data on the frequency and prognostic value of BCL2 positivity are conflicting. We aimed to evaluate BCL2 expression by IHC and assess the prognostic significance of the histopathologically-scored BCL2 expression in 456 patients with DLBCL uniformly treated with standard immunochemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP)...
May 18, 2017: Blood
https://www.readbyqxmd.com/read/28522441/encouraging-activity-for-r-chop-in-advanced-stage-nodular-lymphocyte-predominant-hodgkin-lymphoma
#4
Michelle A Fanale, Chan Yoon Cheah, Amy Rich, L Jeffrey Medeiros, Chao-Ming Lai, Yasuhiro Oki, Jorge E Romaguera, Luis Fayad, F B Hagemeister, Felipe Samaniego, Maria A Rodriguez, Sattva S Neelapu, Hun J Lee, Loretta Nastoupil, Nathan Fowler, Francesco Turturro, Jason Westin, Michael Wang, Peter McLaughlin, Chelsea Pinnix, Sarah Milgrom, Bouthaina Dabaja, Sandra B Horowitz, Anas Younes
Nodular lymphocyte Hodgkin lymphoma (NLPHL) is a rare disease for which the optimal therapy is unknown. We hypothesized R-CHOP could decrease rates of relapse and transformation. We retrospectively reviewed patients with NLPHL diagnosed between 1995 and 2015 confirmed by central pathologic review. Fifty-nine had sufficient treatment and follow-up data for analysis. We described progression-free (PFS), overall survival (OS) and histologic transformation according to treatment strategy and explorede prognostic factors for PFS and OS...
May 18, 2017: Blood
https://www.readbyqxmd.com/read/28509395/da-epoch-r-for-post-transplant-lymphoproliferative-disorders-ptld
#5
Christin B DeStefano, Vera Malkovska, Hind Rafei, Aarthi Shenoy, Kelly Fitzpatrick, Anita Aggarwal, Joseph P Catlett
Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous and potentially fatal group of neoplasms arising in an immunodeficient environment in the background of viral antigenic stimulation. PTLD is rare, with an incidence in solid organ transplant recipients typically less than 20% [1]. For aggressive, monomorphic cases, current guidelines recommend reduced immunosuppression in addition to chemoimmunotherapy, which generally consists of R-CHOP [1]. Nevertheless, prognosis is poor with 5-year overall survival (OS) rates of only 40-60% [1]...
May 16, 2017: European Journal of Haematology
https://www.readbyqxmd.com/read/28498371/low-absolute-peripheral-blood-cd4-t-cell-count-predicts-poor-prognosis-in-r-chop-treated-patients-with-diffuse-large-b-cell-lymphoma
#6
Y Kusano, M Yokoyama, Y Terui, N Nishimura, Y Mishima, K Ueda, N Tsuyama, H Yamauchi, A Takahashi, N Inoue, K Takeuchi, K Hatake
No abstract text is available yet for this article.
May 12, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28489772/primary-diffuse-large-b-cell-lymphoma-of-the-uterine-cervix-successfully-treated-by-combined-chemotherapy-alone-a-case-report
#7
Ana María Cubo, Zandra Mileny Soto, Miguel Ángel Cruz, María José Doyague, Verónica Sancho, Aurymar Fraino, Óscar Blanco, Noemi Puig, Miguel Alcoceba, Marcos González, José María Sayagués
RATIONALE: Primary lymphomas of the uterine cervix are a rare disease. They are often misdiagnosed because of their rarity and because they can be easily confused with a squamous cell carcinoma of the cervix, as they are usually presented as exophytic mass with vaginal bleeding as their most common symptoms. Nevertheless, considering that both the prognosis and the treatment are completely different between them, differential diagnosis should be taken into account. PATIENT CONCERNS: A case of a 51-year-old woman with a primary diffuse large B-cell lymphoma of the cervix is presented...
May 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28489598/prognostic-analysis-of-dlbcl-patients-and-the-role-of-upfront-asct-in-high-intermediate-and-high-risk-patients
#8
Ying Zhao, Hong Wang, Song Jin, Jiajia Zheng, Man Huang, Yaqiong Tang, Zhengming Jin, Huiying Qiu, Xiaowen Tang, Chengcheng Fu, Yue Han, De-Pei Wu
The role of autologous stem cell transplantation (ASCT) as a frontline treatment in patients with diffuse large B cell lymphoma (DLBCL) who are in their first remission has not been fully elucidated in the rituximab era. We analyzed 272 DLBCL patients who received 4-6 cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) or R-CHOP followed by ASCT, from January 2005 to June 2013 in our institution. Multivariate analysis showed the none germinal center B cell (non-GCB) subtype (P=0...
April 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/28487884/diffuse-large-b-cell-lymphoma-can-genomics-improve-treatment-options-for-a-curable-cancer
#9
REVIEW
Amit Dipak Amin, Tara L Peters, Lingxiao Li, Soumya Sundara Rajan, Ramesh Choudhari, Soham D Puvvada, Jonathan H Schatz
Gene-expression profiling and next-generation sequencing have defined diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis, as a heterogeneous group of subentities. Despite ongoing explosions of data illuminating disparate pathogenic mechanisms, however, the five-drug chemoimmunotherapy combination R-CHOP remains the frontline standard treatment. This has not changed in 15 years, since the anti-CD20 monoclonal antibody rituximab was added to the CHOP backbone, which first entered use in the 1970s...
May 2017: Cold Spring Harbor Molecular Case Studies
https://www.readbyqxmd.com/read/28475457/outcomes-of-patients-with-double-hit-lymphoma-who-achieve-first-complete-remission
#10
Daniel J Landsburg, Marissa K Falkiewicz, Joseph Maly, Kristie A Blum, Christina Howlett, Tatyana Feldman, Anthony R Mato, Brian T Hill, Shaoying Li, L Jeffrey Medeiros, Pallawi Torka, Francisco Hernandez-Ilizaliturri, Nishitha M Reddy, Arun Singavi, Timothy S Fenske, Julio C Chavez, Jason B Kaplan, Amir Behdad, Adam M Petrich, Martin A Bast, Julie M Vose, Adam J Olszewski, Cristiana Costa, Frederick Lansigan, James N Gerson, Stefan K Barta, Oscar Calzada, Jonathon B Cohen, Jennifer K Lue, Jennifer E Amengual, Xavier Rivera, Daniel O Persky, David J Peace, Sunita Nathan, Ryan D Cassaday
Purpose Patients with double-hit lymphoma (DHL) rarely achieve long-term survival following disease relapse. Some patients with DHL undergo consolidative autologous stem-cell transplantation (autoSCT) to reduce the risk of relapse, although the benefit of this treatment strategy is unclear. Methods Patients with DHL who achieved first complete remission following completion of front-line therapy with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or intensive front-line therapy, and deemed fit for autoSCT, were included...
May 5, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28471564/integration-of-ct-based-measurements-into-surveillance-pet-ct-in-patients-with-diffuse-large-b-cell-lymphoma
#11
Noa Lavi, Gali Shapira, Ariel Zilberlicht, Noam Benyamini, Dan Farbstein, Eldad J Dann, Rachel Bar-Shalom, Irit Avivi
BACKGROUND: Despite the lack of clinical studies supporting the use of routine surveillance FDG-positron emission tomography (PET) in patients with diffuse large B cell lymphoma (DLBCL) who achieved remission, many centers still use this strategy, especially in high risk patients. Surveillance FDG-PET computed tomography (CT) is associated with a high false positive (FP) rate in DLBCL patients. OBJECTIVES: To investigate whether use of specific CT measurements could improve the positive predictive value (PPV) of surveillance FDG-PET/CT...
July 2016: Israel Medical Association Journal: IMAJ
https://www.readbyqxmd.com/read/28461685/intravascular-large-b-cell-lymphoma-presenting-as-fever-of-unknown-origin-and-diagnosed-by-random-skin-biopsies-a-case-report-and-literature-review
#12
Horacio di Fonzo, Damian Contardo, Diego Carrozza, Paola Finocchietto, Adriana Rojano Crisson, Cecilia Cabral, Maria de Los Angeles Juarez
BACKGROUND Intravascular lymphoma (IVL) is a rare lymphoproliferative disorder characterized by the proliferation of large B lymphoma cells within the lumen of small-caliber blood vessels. Clinical features are nonspecific, presenting as a systemic disease with fever and may be life-threatening. Antemortem diagnosis is difficult but may be made with biopsies of affected tissues or with random skin biopsies. CASE REPORT We report the case of a 66-year-old white woman presenting with fever of unknown origin (FUO) who developed neurologic, pulmonary, and hematologic manifestations...
May 2, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28449294/analysis-of-the-prognostic-value-of-bmi-and-the-difference-in-its-impact-according-to-age-and-sex-in-dlbcl-patients
#13
Yusuke Kanemasa, Tatsu Shimoyama, Yuki Sasaki, Miho Tamura, Takeshi Sawada, Yasushi Omuro, Tsunekazu Hishima, Yoshiharu Maeda
Studies that have evaluated the prognostic value of body mass index (BMI) in patients with diffuse large B-cell lymphoma have recently been reported. However, the impact of BMI on survival outcomes remains controversial. We retrospectively analyzed the data of 406 diffuse large B-cell lymphoma patients treated with R-CHOP or R-CHOP-like regimens. The number (%) of patients that were categorized into 1 of 4 groups according to BMI were underweight (<18.5 kg/m(2) ), 58 (14.3%); normal weight (≥18.5 to <25 kg/m(2) ), 262 (64...
April 27, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28446287/-prognostic-significance-of-follicular-lymphoma-international-prognostic-index-2-flipi2-in-follicular-lymphoma-patients-treated-with-rituximab-maintenance
#14
Peng-Peng Xu, Ying Qian, Qiu-Sheng Chen, Liang-Qun Li, Li Zhang, Wei-Li Zhao
OBJECTIVE: To investigate the prognostic significance of Follicular Lymphoma International Prognostic Index 2 (FLIPI2) in FL patients treated with rituximab maintenance. METHODS: A tatol of 140 newly diagnosed FL patients who received Rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) chemotherapy in our department were retrospectively analyzed from December 2002 to December 2014. Among 140 patients with FL 122 patients achieved response, from them 56 patients received R maintenance (RM) every 2 months for median 8 times (RM group) while the rest 66 patients did not receive further anti-lymphoma treatment (non-RM group)...
April 2017: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/28434928/hypercvad-chemotherapy-in-mantle-cell-lymphoma-patients-is-associated-with-higher-rates-of-hematopoietic-progenitor-cell-mobilization-failure-despite-plerixafor-rescue
#15
Amandeep Salhotra, Yuan Shan, Ni-Chun Tsai, James F Sanchez, Ibrahim Aldoss, Haris Ali, Tanya Paris, Ricardo Spielberger, Thai M Cao, Auayporn Nademanee, Stephen J Forman, Robert Chen
Induction regimens for mantle cell lymphoma (MCL) can be categorized into highly intensive ones containing cytarabine and less intense regimens such as R (rituximab) CHOP or R-bendamustine. Prior publications have shown R-hyperCVAD can be associated with stem cell mobilization failures. However, those studies did not include the use of plerixafor as rescue for stem cell mobilization failure. We examined our database of 181 consecutive MCL patients from 2005 to 2015 who received upfront therapy with either R-hyperCVAD or less intense chemotherapy (R-bendamustine and R-CHOP only) regimens to assess impact of frontline chemotherapy on collection of hematopoietic cell progenitors prior to autologous stem cell transplant (ASCT)...
April 18, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28432650/efficacy-and-tolerability-of-a-2-year-rituximab-maintenance-therapy-in-patients-with-advanced-follicular-lymphoma-after-induction-of-response-with-rituximab-containing-first-line-regimens-husom-study
#16
Tamás Schneider, András Rosta, Hajna Losonczy, Gáspár Radványi, György Ujj, Miklós Egyed, Árpád Illés, János Jakucs, László Szerafin, Zoltán Gasztonyi, Tamás Masszi, János Iványi, Judit Demeter, Péter Dombi, Antal Tóth, Zita Borbényi
Follicular lymphoma is a lymphoid malignancy commonly showing slow progression which makes the treatment of the disease challenging. Rituximab monotherapy and rituximab added to standard chemotherapy has been proven to increase survival among patients with advanced stage of the disease. However, the benefit of a rituximab maintenance therapy after induction was still unclear at the time of the initiation of this study. HUSOM was a phase III open-label, single-arm, multi-centre study aimed to assess the efficacy and the safety of the 12 cycles of rituximab (375 mg/m(2) every 8 weeks) maintenance therapy in patients had already presented partial or complete response to R-CVP or R-CHOP...
April 21, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/28430649/abcg2-and-ncf4-polymorphisms-are-associated-with-clinical-outcomes-in-diffuse-large-b-cell-lymphoma-patients-treated-with-r-chop
#17
Duo Liu, Nan Wu, Haiming Sun, Mei Dong, Tianzhu Guo, Peng Chi, Guofu Li, Donglin Sun, Yan Jin
The impact of pharmacogenetics on predicting survival in diffuse large B-cell lymphoma (DLBCL) remains unclear. We tested 337 DLBCL patients treated with rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for 9 single nucleotide polymorphisms from 6 genes (CD20, FCGR2A, NAD(P)H, ABCC2, ABCG2 and CYP3A5). Patients who carried the NCF4 rs1883112 GG genotype showed significantly shorter progression-free survival (PFS) (P = 0.023) and event-free survival (EFS) (P < 0.001) comparing with A allele...
April 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/28430176/low-absolute-peripheral-blood-cd4-t-cell-count-predicts-poor-prognosis-in-r-chop-treated-patients-with-diffuse-large-b-cell-lymphoma
#18
Y Kusano, M Yokoyama, Y Terui, N Nishimura, Y Mishima, K Ueda, N Tsuyama, Y Hirofumi, A Takahashi, N Inoue, K Takeuchi, K Hatake
The absolute peripheral blood lymphocyte count at diagnosis is known to be a strong prognostic factor in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), but it remains unclear as to which peripheral blood lymphocyte population is reflective of DLBCL prognosis. In this cohort, 355 patients with DLBCL treated with R-CHOP from 2006 to 2013 were analyzed. The low absolute CD4+ T-cell count (ACD4C) at diagnosis negatively correlated with the overall response rate and the complete response rate significantly (P<0...
April 21, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28426350/lenalidomide-maintenance-compared-with-placebo-in-responding-elderly-patients-with-diffuse-large-b-cell-lymphoma-treated-with-first-line-rituximab-plus-cyclophosphamide-doxorubicin-vincristine-and-prednisone
#19
Catherine Thieblemont, Hervé Tilly, Maria Gomes da Silva, Rene-Olivier Casasnovas, Christophe Fruchart, Franck Morschhauser, Corinne Haioun, Julien Lazarovici, Anida Grosicka, Aurore Perrot, Judith Trotman, Catherine Sebban, Dolores Caballero, Richard Greil, Koen van Eygen, Amos M Cohen, Hugo Gonzalez, Reda Bouabdallah, Lucie Oberic, Bernadette Corront, Bachra Choufi, Armando Lopez-Guillermo, John Catalano, Achiel Van Hoof, Josette Briere, Jose Cabeçadas, Gilles Salles, Philippe Gaulard, Andre Bosly, Bertrand Coiffier
Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Lenalidomide, an immunomodulatory agent, has shown activity in DLBCL. This randomized phase III trial compared lenalidomide as maintenance therapy with placebo in elderly patients with DLBCL who achieved a complete response (CR) or partial response (PR) to R-CHOP induction. Methods Patients with previously untreated DLBCL or other aggressive B-cell lymphoma were 60 to 80 years old, had CR or PR after six or eight cycles of R-CHOP, and were randomly assigned to lenalidomide maintenance 25 mg/d or placebo for 21 days of every 28-day cycle for 24 months...
April 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28423544/cell-of-origin-of-diffuse-large-b-cell-lymphomas-determined-by-the-lymph2cx-assay-better-prognostic-indicator-than-hans-algorithm
#20
Nara Yoon, Soomin Ahn, Hae Yong Yoo, Suk Jin Kim, Won Seog Kim, Young Hyeh Ko
Diffuse large B-cell lymphomas (DLBCLs) are clinically heterogeneous and need a biomarker that can predict the outcome of treatments accurately. To assess the prognostic significance of the cell-of-origin type for DLBCLs, we applied the Lymph2Cx assay using a NanoString gene expression platform on formalin-fixed paraffin wax-embedded pretreatment tissues obtained from 82 patients with de novo DLBCL, not otherwise specified. All patients were treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as the first line of chemotherapy...
March 28, 2017: Oncotarget
keyword
keyword
12044
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"